This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The multiple regression analysis showed that the adjusted odds ratio (OR) in the full sample was 2.466 (95% confidence interval, CI: 2.30 -2.726) for light smokers, 3.018 (95% CI: 2.649 -3.438) for moderate smokers and 3.221 (95% CI: 2.418 -4.289) for heavy smokers. This means that prenatal maternal smoking more than doubled the estimated risk of SIDS.
Among the other correlates, the most important results suggested that race/ethnicity was strongly correlated with SIDS risk. Infants born to black people had a higher risk of SIDS, while those born to Hispanics or Latinos experienced a significantly lower risk than those born to non-Hispanic whites.
The conditional logistic regression confirmed the previous findings. The adjusted OR was 2.511 (95% CI: 2.26 -2.789) for light smokers, 3.249 (95% CI: 2.835 -3.723) for moderate smokers and 3.847 (95% CI: 2.866 -5.162) for heavy smokers.
Clinical conclusions
The effectiveness analysis showed that maternal smoking had a significant and strong effect on the risk of SIDS.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic analysis was the number of SIDS deaths averted if pregnant smokers enrolled in a typical smoking cessation programme, compared with no intervention. This was based on the adjusted ORs calculated in the effectiveness study, assuming that a typical smoking cessation intervention would result in a quit rate of about 15% among pregnant smokers (see Other Publications of Related Interest).
Direct costs
The cost of the smoking cessation programme was derived from a published study (see Other Publications of Related Interest). Details of the study were not reported. The cost categories included in the analysis and the cost/resource boundary adopted were also not stated. The costs were estimated in 1986 values and then inflated to 1998 values. The cost of the comparator (no smoking cessation intervention) was likely to have been 0.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included in the economic analysis.
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Sensitivity analysis
Sensitivity analyses were not conducted.
Estimated benefits used in the economic analysis
Compared with no intervention, the number of SIDS deaths averted if pregnant smokers enrolled in a typical smoking cessation programme was 108 (95% CI: 102 -114) for all pregnant smokers, 63 (95% CI: 58 -68) for those smoking 1 to 10 cigarettes/day, 39 (95% CI: 36 -41) for those smoking 11 to 20 cigarettes/day, and 6.9 (95% CI: 5.9 -7.6) for those smoking more than 20 cigarettes/day.
If all pregnant smokers were to cease smoking (regardless of the smoking cessation programme), the corresponding figures would be 722 (95% CI: 677 -763) for all smokers, 422 (95% CI: 388 -453) for light smokers, 258 (95% CI: 239 -274) for moderate smokers, and 46 (95% CI: 40 -50) for heavy smokers.
Cost results
The study that provided the cost data estimated that a smoking cessation programme cost $45 per participant at 1998 values. The total costs were not reported.
Synthesis of costs and benefits
An incremental cost-effectiveness ratio was calculated to combine the costs and benefits of the study intervention.
Relative to no intervention, the estimated cost per averted SIDS death for the smoking cessation programme was $210,500 (95% CI: 119,200 -224,400) for all pregnant smokers, $235,400 (95% CI: 219,300 -256,400) for those smoking 1 to 10 cigarettes/day, $177,300 (95% CI: 166,800 -191,100) for those smoking 11 to 20 cigarettes/day, and $151,000 (95% CI: 137,200 -174,500) for those smoking more than 20 cigarettes/day.
Authors' conclusions
The smoking cessation programme cost $210,500 per sudden infant death syndrome (SIDS) death averted, although it had a modest impact on the population incidence of SIDS. Assuming a 75.4-year estimated life expectancy for infants who survived to 1 year of age, and a conventional 5% annual discount rate, then the prenatal smoking cessation programme cost less than $11,000 per life-year. This represents a reasonable figure for a programme that improves public health.
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparator was clear. No intervention was selected as the basic comparator because it represented the standard approach. Also, the aim of the study was to estimate the additional costs of the smoking cessation programme. You should decide whether no programme is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness used a historical cross-sectional study, which was useful as it offered the picture of the incidence of disease in a specific birth cohort in the USA. However, exposure and disease were evaluated at the same time and no explicit comparator was considered. Indeed, the effectiveness study aimed to estimate the relationship between a specific factor (prenatal maternal smoking) and the incidence of disease, although the author stated that "the precise etiology of this relationship is unknown". A further limitation of the analysis was the use of self-reported data, which, as the author acknowledged, cast some doubts on the observed results of the analysis. Data on postnatal smoking and other household tobacco exposures were unavailable. The value of reduced smoking among women who relapsed was not considered. The author also stressed that sub-group analyses should have focused on specific ethnic groups,
